ARYA Sciences Acquisition Corp. III (ARYA): Price and Financial Metrics


ARYA Sciences Acquisition Corp. III (ARYA): $11.16

0.48 (+4.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ARYA Stock Price Chart Interactive Chart >

Price chart for ARYA

ARYA Price/Volume Stats

Current price $11.16 52-week high $25.89
Prev. close $10.68 52-week low $9.82
Day low $10.77 Volume 366,200
Day high $11.25 Avg. volume 320,123
50-day MA $11.23 Dividend yield N/A
200-day MA $11.72 Market Cap 186.48M

ARYA Sciences Acquisition Corp. III (ARYA) Company Bio


ARYA Sciences Acquisition Corp III intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was founded in 2020 and is based in New York, New York.


ARYA Latest News Stream


Event/Time News Detail
Loading, please wait...

ARYA Latest Social Stream


Loading social stream, please wait...

View Full ARYA Social Stream

Latest ARYA News From Around the Web

Below are the latest news stories about ARYA Sciences Acquisition Corp III that investors may wish to consider to help them evaluate ARYA as an investment opportunity.

Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome

Business combination transaction with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors, closed on June 9, 2021Publicly traded company renamed Nautilus Biotechnology, Inc.Common stock commences trading under ticker symbol “NAUT” on the Nasdaq Global Select Market on June 10, 2021Gross proceeds from this transaction to Nautilus totaled approximately $345 million, combining approximately $145 million of funds held in Arya III’s trust account

Yahoo | June 10, 2021

ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp III (“ARYA”) (Nasdaq: ARYA), today announced that, due to the public health and safety concerns related to the coronavirus (COVID-19) pandemic and recommendations and orders from federal and New York authorities, ARYA is strongly encouraging that shareholders attend the extraordinary general meeting of its shareholders on June 8, 2021 at 9:00 a.m., New York City Time (the “General Meeting”) remotely by teleconference rath

Yahoo | June 1, 2021

3 Biotech Stocks That Could Double In 12 Months

Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fundamentals, key make-or-break events and cash runway — can fetch disproportionate returns. Here are three biopharma stocks that have the potential to more than double from current levels: Immatics (NASDAQ: IMTX ) FibroGen, Inc. (NASDAQ: FGEN ) Replimune Group, Inc. (NASDAQ: REPL ) Immatics: Immatics is a clinical-stage biopharma engaged in the discovery and development of T cell directing cancer immunotherapies. The shares of the German biotech were listed on the Nasdaq in July 2020 following its business combination with Arya Sciences Acquisition Corp, a SPAC sponsored by Perceptive Advis...

Benzinga | March 17, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds ARYA, GLUU, AJRD and RP Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | February 16, 2021

Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics

Arya Sciences Acquisition Corp. (NASDAQ: ARYA or "Arya"), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH ("Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced that its respective shareholders approved the business combination between Arya and Immatics announced on March 17, 2020. None of Arya’s shareholders redeemed their shares in connection with the ARYA shareholder approval. The respective boards of directors of both Arya and Immatics had previously approved the business combination.

Yahoo | June 29, 2020

Read More 'ARYA' Stories Here

ARYA Price Returns

1-mo 9.95%
3-mo -19.65%
6-mo 2.95%
1-year -27.81%
3-year N/A
5-year N/A
YTD 2.86%
2020 N/A
2019 0.00%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9758 seconds.